Anthony Hartness
Optometrist · Augusta, KSNPI 1326230657
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,960 of the $7,811 with a category attached, or 63.5%. 12 manufacturers reported payments, led by Carl Zeiss Meditec USA, Inc. at 36.5% of the total. Reporting peaked in 2021 at $3,549 and has fallen 88.4% since, to $412 in 2025. Among optometrist clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 124 payments — averaging $63.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec USA, Inc.$3K
- Alcon$2K
- Biotissue Holdings Inc.$884
- Coopervision Inc.$727
- Bausch & Lomb, A Division Of Bausch Health US, LLC$529
- Johnson & Johnson Vision Care, Inc.$390
- plus $793 from 6 others
What the payments were for
- Food & beverage$4,96063%
- Other$2,85137%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec USA, Inc. | 1 | $2,851 |
| Alcon | 44 | $1,638 |
| Biotissue Holdings Inc. | 14 | $884 |
| Coopervision Inc. | 21 | $727 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $529 |
| Johnson & Johnson Vision Care, Inc. | 12 | $390 |
| Bausch & Lomb Americas Inc. | 14 | $348 |
| Sight Sciences, Inc. | 2 | $236 |
| Alcon Research LLC | 1 | $105 |
| Ivantis, Inc | 1 | $68 |
| Tarsus Pharmaceuticals, Inc. | 1 | $22 |
| AbbVie | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CIRRUS 5000$2,851
- DAILIES$545
- Precision 1$451
- Prokera$245
- TEARCARE SYSTEM$236
- INFUSE$226
- Acuvue$147
- ULTRA$123
- BIOTRUE$123
- BIOTRUE ONE DAY$123
- MyDay Contact Lens$122
- AmnioGraft$108
- MiSight Contact Lens$102
How this compares
$7,811 in reported general payments places this provider in the 95th percentile of 567 optometrist providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 21 | $24,133 |
| RestasisCyclosporine | 21 | $17,322 |
| LumiganBimatoprost | 50 | $12,220 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 146 | $2,550 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $1,492 |
| Latanoprost | 294 | $1,362 |
| Brimonidine Tartrate | 61 | $869 |
| Timolol Maleate | 65 | $812 |
| Difluprednate | 13 | $729 |
| Dorzolamide Hcl | 29 | $560 |
| Prednisolone Acetate | 20 | $525 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 11 | $102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $15 | $29,54271 claims |
| Bausch & Lomb Americas Inc.Xiidra | $348 | $24,13321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 567 optometrist providers in Kansas.
Other optometrist in Augusta
- Jeffry GersonOlathe$619K
- Shane KannarrPittsburg$529K
- Jason PingelMission$244K
- Justin WeigelOlathe$220K
- Chad ThompsonBeloit$96K
- Brandon HunterLeawood$68K
- Raymond BrillMission$19K
- Vincent PennipedeOverland Park$16K
- Ryan WineingerShawnee$13K
- Diana CarrigerTopeka$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.